English
|
简体中文
|
繁體中文
|
한국어
|
日本語
Home
|
About us
|
Services
|
Partners
|
Events
|
Contact us
|
Login
Friday, April 19, 2024
Press Releases for Wednesday, November 16, 2022
American Journal of Gastroenterology Publishes Data from HighTide Therapeutics' Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis
23:00 HKT/SGT
Samaiden Posts 71.82% Revenue Increase in 1Q FY2023
19:00 HKT/SGT
HKTDC Entrepreneur Day and Business of IP Asia Forum start from late November
18:00 HKT/SGT
Moonstake、CMOのPietro Curtoの就任により経営体制を強化
18:00 HKT/SGT
日立、DX・クラウド事業の拡大に向け組織・体制強化
16:30 HKT/SGT
Moonstake, 분산된 ETH 스테이킹 통합을 위해 ssv.network에서 보조금 지원 확정 발표
16:00 HKT/SGT
Moonstakeがssv.networkの助成金を受領―分散型ETHステーキングの統合へ
16:00 HKT/SGT
Moonstake Receives ssv.network Grant to Integrate Decentralized ETH Staking
16:00 HKT/SGT
NEC、建設業許可を再取得
15:00 HKT/SGT
TOYOTA、新型「プリウス」を世界初公開
13:50 HKT/SGT
Crypto Oasis Joins Algorand's "Decipher" Conference as Regional Partner
13:40 HKT/SGT
Pertamina Geothermal Energy (PGE) to increase GPP in South Sumatra to support NZE in Indonesia
13:00 HKT/SGT
World Premiere of All-New Prius in Japan
12:59 HKT/SGT
Mintable Now Supports NFT Transactions and Minting on the XRP Ledger
11:00 HKT/SGT
Metoject Subcutaneous Injection Syringe (Methotrexate) Launched In Japan For Rheumatoid Arthritis
10:46 HKT/SGT
复星「减肥」背后:旨在聚焦主业,加强创新和全球化
10:13 HKT/SGT
復星「瘦身」背後:旨在聚焦主業,加強創新和全球化
10:12 HKT/SGT
The Logic Behind Fosun's "Weight-loss" Actions: To Focus on the Core Businesses and Deepen Innovation and Globalization
10:11 HKT/SGT
《美國胃腸病學雜誌》發表君聖泰HTD1801 治療原發性硬化性膽管炎的臨床 II 期研究數據
10:01 HKT/SGT
《美国胃肠病学杂志》发表君圣泰HTD1801 治疗原发性硬化性胆管炎的临床 II 期研究数据
10:00 HKT/SGT
エーザイと日本メダック、「メトジェクト(R)皮下注シリンジ」(一般名:メトトレキサート)を日本において関節リウマチの効能・効果で新発売
08:30 HKT/SGT
Why Turkeys Should Give Thanks This Thanksgiving
04:30 HKT/SGT
ACN Search:
Eesee Implements Blockpass for Compliance in Digital Assets Marketplace
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home
|
About us
|
Services
|
Partners
|
Events
|
Login
|
Contact us
|
Cookies Policy
|
Privacy Policy
|
Disclaimer
|
Terms of Use
|
RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575